Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03334721 · ClinicalTrials.gov registry record · Phase 2
Gabapentin for Bipolar & Cannabis Use Disorders
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03334721 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 23 participants.
The verdict
NCT03334721, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The proposed 2-week, double-blind, crossover, proof of concept study aims to measure and manipulate core neurochemical (i.e., dysregulated brain GABA/glutamate homeostasis) and neurobehavioral (i.e., elevated impulsivity) dysfunctions characteristic of individuals with cannabis use disorder (CUD) and Bipolar Disorder (BD), using a medication that has been shown to increase cortical GABA (i.e., gabapentin) levels in past research, and to evaluate medication-related changes in response inhibition (go no-go) and cannabis cue reactivity functional Magnetic Resonance Imaging tasks, as well as cannabis use, mood symptoms (including anxiety and sleep), and impulsivity in individuals with CUD+BD.
Interventions
- DRUG Placebo Oral Capsule
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03334721
The ClinicalTrials.gov registry entry for NCT03334721 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03334721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03334721 about?
NCT03334721 is a clinical study titled "Gabapentin for Bipolar & Cannabis Use Disorders". The proposed 2-week, double-blind, crossover, proof of concept study aims to measure and manipulate core neurochemical (i.e., dysregulated brain GABA/glutamate homeostasis) and neurobehavioral (i.e., elevated impulsivity) dysfunctions characteristic of individuals with cannabis use disorder (CUD) an...
What is the current status of trial NCT03334721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-10-01. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT03334721?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT03334721?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.